[{"id":"tazemetostat","kind":"drug","name":"Tazemetostat","route":"/drugs/tazemetostat/","commit":"0bdbdae6c6","date":"2026-09-09","author":"Jude Gomila","message":"Editing pass: every TL;DR and summary stands alone","file":"src/data/gap-fill.ts","type":"changed","fields":[{"field":"tldr","before":"\"The first EZH2 inhibitor, approved for epithelioid sarcoma and follicular lymphoma in 2020 and withdrawn worldwide in 2026 after secondary blood cancers.\"","after":"\"Tazemetostat was the first EZH2 inhibitor, approved for epithelioid sarcoma and follicular lymphoma in 2020 and withdrawn worldwide in 2026 after secondary blood cancers.\""}]},{"id":"tazemetostat","kind":"drug","name":"Tazemetostat","route":"/drugs/tazemetostat/","commit":"71e4eef6e1","date":"2026-09-08","author":"Jude Gomila","message":"Gap audit and gap-fill data: 33 cancers, 87 products, 20 targets, 25 technologies, 12 terms, 18 collections","file":"src/data/gap-fill.ts","type":"added","fields":[{"field":"id"},{"field":"name"},{"field":"brand"},{"field":"modality"},{"field":"mechanism"},{"field":"status"},{"field":"wikipedia"},{"field":"tldr"},{"field":"summary"},{"field":"approvals"},{"field":"targets"},{"field":"cancers"},{"field":"companies"},{"field":"technologies"},{"field":"regulatoryEvents"},{"field":"links"},{"field":"tags"}]}]